Австралія - англійська - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 250 microgram/actuation; salmeterol xinafoate, quantity: 36.3 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: *patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids. *patients who are symptomatic on current inhaled corticosteroid therapy. for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. seretide is not indicated for the initiation of bronchodilator therapy in copd.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 125 microgram/actuation; salmeterol xinafoate, quantity: 36.3 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: *patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids. *patients who are symptomatic on current inhaled corticosteroid therapy. for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. seretide is not indicated for the initiation of bronchodilator therapy in copd.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 50 microgram/actuation; salmeterol xinafoate, quantity: 36.3 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: *patients on effective maintenance doses of long-acting beta-2-agonists and inhaled corticosteroids. *patients who are symptomatic on current inhaled corticosteroid therapy.*initiation of maintenance therapy in those patients with moderate persistent asthma not adequately controlled on "as needed" reliever medication, and who have moderate/severe airway limitation and daily symptoms requiring medication every day (see clinical trials). for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. seretide is not indicated for the initiation of bronchodilator therapy in copd.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - live varicella vaccine, quantity: 1995 pfu; rubella virus, quantity: 1000 ccid50; measles virus, quantity: 1000 ccid50; mumps virus, quantity: 25119 ccid50 - diluent, not applicable - excipient ingredients: water for injections - priorix-tetra is indicated for active immunisation against measles, mumps, rubella and varicella from 9 months of age.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - measles virus, quantity: 1000 ccid50; rubella virus, quantity: 1000 ccid50; mumps virus, quantity: 25119 ccid50; live varicella vaccine, quantity: 1995 pfu - diluent, not applicable - excipient ingredients: water for injections - priorix-tetra is indicated for active immunisation against measles, mumps, rubella and varicella from 9 months of age.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - rubella virus, quantity: 1000 ccid50; mumps virus, quantity: 25119 ccid50; measles virus, quantity: 1000 ccid50; live varicella vaccine, quantity: 1995 pfu - injection, powder for - excipient ingredients: mannitol; sorbitol; lactose; threonine; serine; proline; glycine; alanine; valine; methionine; isoleucine; leucine; tyrosine; phenylalanine; tryptophan; lysine hydrochloride; histidine; arginine - priorix-tetra is indicated for active immunisation against measles, mumps, rubella and varicella from 9 months of age.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - measles virus, quantity: 1000 ccid50; mumps virus, quantity: 5000 ccid50; rubella virus, quantity: 1000 ccid50 - diluent, not applicable - excipient ingredients: water for injections - priorix is indicated for active immunisation against measles, mumps and rubella from 12 months of age.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - atovaquone, quantity: 62.5 mg; proguanil hydrochloride, quantity: 25 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; magnesium stearate; hypromellose; macrogol 8000; microcrystalline cellulose; titanium dioxide; poloxamer; hyprolose; povidone; macrogol 400; iron oxide red - prophylaxis of plasmodium falciparum malaria in adults and children 11kg and over; treatment of plasmodium falciparum malaria in adults and children aged 3 years or older.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 50 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for use in the prophylactic management of asthma in adults and in children ages 1 year and older.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salmeterol xinafoate, quantity: 72.5 microgram/actuation (equivalent: salmeterol, qty 50 microgram/actuation); fluticasone propionate, quantity: 500 microgram/actuation - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids. patients who are symptomatic on current inhaled corticosteroid therapy. initiation of maintenance therapy in those patients with moderate persistent asthma not adequately controlled on as needed reliever medication, and who have moderate/severe airway limitation and daily symptoms requiring reliever medication every day (see clinical trials). for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. seretide is not indicated for the initiation of bronchodilator therapy in copd.